155,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in 1-2 Wochen
  • Gebundenes Buch

Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Therapeutic options for patients with myeloma have dramatically changed over the past 10 years. Beginning with the advances in therapy resulting from the use of high-dose therapy and autologous bone marrow or stem cell tra- plant, we have more than doubled the median survival for patients as a whole, and have now have a wealth of different biology -based treatment approaches for our patients in all disease stages. This book represents state-of-the-art information from many of the leaders in the plasma cell disorders world. Sections focusing on disease pathogenesis and biology, chemotherapy-based approaches, immune -based therapies, currently approved novel agents, developing targets, supportive care, and other plasma cell disorders provides a comprehensive collection and an excellent resource in this time of rapid change in clinical and preclinical disease knowledge. It is important to realize that these changes did not occur in a vacuum. Partnerships between academic institutions, the pharmaceutical industry, patient advocacy groups, the National Cancer Institute, community onco- gists, and ultimately our patients worked closely together to realize these advances, and to effect the radical changes in therapy we have witnessed over the past few years. This book would not have been possible without contri- tions from each of the gifted scientists and clinicians who worked tirelessly to prepare their individual chapters all the while maintaining commitment to the scientific and clinical mission of advancing care.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Rezensionen
From the reviews:

"The book Myeloma Therapy: Pursuing the Plasma Cell, edited by Sagar Lonial, arrives just in time. ... a comprehensive, updated review of all the problems concerning myeloma. The authors are among the world's top scientific leaders in this field ... . Consultation and systematic reading are interesting, useful, and very agreeable. It cannot be lacking in the library of the hematologists and oncologists taking care of myeloma patients, and it's also a worthwhile volume for scientists involved in preclinical research." (Sergio Storti, Laboratory Hematology, Vol. 15 (34), 2009)

"Myeloma therapy by Sagar Lonial deals with various aspects of the plasma cell disorders and multiple myeloma in particular. ... this is a goldmine of information written in a style that is accessible to the biochemically interested clinician. ... is highly recommended to the advanced reader in this field. It is a reference work on both clinical and biological aspects of multiple myeloma and should be part of the libraries of hospitals for physicians who are professionally frequently involved with the treatment of this disease." (F. Offner, Acta Clinica Belgica, Vol. 65 (3), 2010)